Manoranjan Das
About Manoranjan Das
Manoranjan Das is the Director of Global Drug Development IT at Bristol Myers Squibb, with extensive experience in clinical operations and IT management.
Company
Manoranjan Das is currently working at Bristol Myers Squibb, serving as the Director of Global Drug Development IT.
Title
Manoranjan Das holds the title of Director, Global Drug Development IT at Bristol Myers Squibb.
Education and Expertise
Manoranjan Das studied at Columbia Business School, where he earned a Master of Business Administration (MBA) from 2021 to 2023. In 2020, he completed a Mini MBA in BioPharma Innovation at Rutgers Business School. Prior to that, he earned a B.E. in Engineering from the Birla Institute of Technology and Science, Pilani from 1996 to 2000.
Background
Manoranjan Das has a rich professional history in the field of IT and pharmaceuticals. He previously worked at Bristol Myers Squibb as Associate Director, Clinical Operations IT from 2016 to 2019. He served as Senior Manager, Clinical Applications at Allergan from 2013 to 2016 and as IT Technical Lead (Siebel CTMS) at Warner Chilcott from 2012 to 2013. Prior experiences also include his role as Manager, Professional Services at C3i Solutions from 2004 to 2012 and as Senior Consultant, IT Consulting at Capgemini from 2002 to 2004. He initially began his career as Associate Consultant at i-flex solutions from 2000 to 2002.
Achievements
Manoranjan Das has led the implementation of global clinical trial management systems that streamlined operations across multiple regions. At Bristol Myers Squibb, he played a key role in digital transformation initiatives focusing on patient engagement and site collaboration. He developed strategic roadmaps for IT business partnerships in global drug operations, enhancing clinical data management and trial transparency. Additionally, he managed a high-performing team responsible for transformational projects in investigator-sponsored trials and contributed to the successful integration of IT systems during mergers and acquisitions in the pharma industry.